[Correspondence] Drawing conclusions from the VIVA trial (Lancet)

The VIVA trial by Jes Lindholt and Rikke Søgaard (Nov 18, 2017, p 2256)1 assessed the effects of screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, showing a small but statistically significant reduction in total mortality in the screening group versus the non-screening group. The authors concluded that `the observed reduction of mortality risk from abdominal aortic aneurysm, peripheral arterial disease, and hypertension` should lead policy makers to `consider implementing combined screening`.